GlobeNewswire·Nov 9, 2026, 4:01 PM ET

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

ANNX

Annexon Inc. advanced two registrational programs with blockbuster potential: tanruprubart for Guillain-Barré syndrome (GBS) and vonaprument for geographic atrophy (GA).
Tanruprubart U.S. and EU FORWARD data strengthens the Biologics License Application (BLA) submission package anticipated in the fourth quarter of 2026, while the EU Marketing Authorisation Application (MAA) is currently under review by the European Medicines Agency (EMA).
The ARCHER II Phase 3 trial for vonaprument is on track to assess the Month 15 primary endpoint for vision protection in the fourth quarter of 2026, with potential sub-study results expected in Q1 2027.
ANX1502, a potential first oral C1s inhibitor for autoimmune diseases including generalized myasthenia gravis (gMG), showed positive proof-of-concept data in cold agglutinin disease, with tablet formulation optimization underway.
Annexon secured a strategic credit facility of up to $200 million with Oxford Finance LLC, drawing an initial $50 million at closing.
The company appointed Mark S. Blumenkranz to its Board of Directors and expanded its Scientific Advisory Board and executive team with retinal specialists to strengthen its ophthalmology franchise.
As of September 30, 2026, cash, cash equivalents, and short-term investments totaled $213.4 million, providing an operating runway into 2028.
Third quarter 2026 financial results reported research and development expenses of $41.4 million and general and administrative expenses of $10.9 million.
The company reported a net loss of $51.2 million, or $0.25 per share, for the quarter ended September 30, 2026.

Company: Annexon Biosciences
Keywords: Nasdaq:ANNX, Annexon Biosciences